Rhythm Pharmaceuticals (RYTM) announced that Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity were published in The New England Journal of Medicine (NEJM). While the release does not cite specific efficacy/safety figures in the article text, NEJM publication of pivotal trial data is a positive scientific milestone that can support future regulatory and commercial momentum.
Rhythm Pharmaceuticals (RYTM) announced that Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity were published in The New England Journal of Medicine (NEJM). While the release does not cite specific efficacy/safety figures in the article text, NEJM publication of pivotal trial data is a positive scientific milestone that can support future regulatory and commercial momentum.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
